TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Prescient Therapeutics Limited ( (AU:PTX) ) has issued an announcement.
Prescient Therapeutics Limited has successfully completed a $9.8 million capital raise, bolstering its cash reserves to $12.32 million as of September 2025. The funds will support the ongoing Phase 2 clinical trial of PTX-100, with promising data from a sub-analysis of a Phase 1b trial showing a 43% overall response rate in patients with relapsed and refractory Cutaneous T Cell Lymphoma. The company is expanding its clinical trial sites in Australia, the United States, and potentially Europe, with an orphan drug designation application submitted to the European Medicines Agency. These developments are expected to enhance Prescient’s industry positioning and provide potential market exclusivity in the European Union.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited is a clinical stage oncology company focused on developing targeted therapies for cancer. The company is actively working on advancing its first-in-class cancer treatment, PTX-100, through clinical trials and towards regulatory approval, addressing significant unmet medical needs.
Average Trading Volume: 1,084,011
Technical Sentiment Signal: Sell
Current Market Cap: A$45.22M
Find detailed analytics on PTX stock on TipRanks’ Stock Analysis page.